Remove Competition Remove Healthcare Provider Remove White Paper
article thumbnail

A Modular Approach to Personalized Engagement

PM360

During the COVID-19 pandemic, pharma organizations built new digital and virtual channels to communicate with healthcare providers (HCPs) outside of their offices. The channels alone aren’t going to produce the desired uptick in engagement without content that’s customized for each channel and personalized for each provider.

article thumbnail

How to Balance Innovation and Compliance for Happier, Healthier Patients

Salesforce

Security and regulatory implications of digital transformation in healthcare As HLS organizations move quickly to innovate, they must also safeguard data, comply with regulations, and protect their systems from cyber threats. And in healthcare, data security is more than a technical issue — it’s about maintaining trust.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Choosing the Right Prospects: A Sales Rep’s Guide

Pharmaceutical Representative Training

Introduction In today’s competitive business environment, sales professionals face the challenge of optimizing their time and resources to achieve success. In this competitive world of sales, especially in pharmaceuticals, the mantra “quality over quantity” holds true.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

16,17 However, care must be taken to ensure that chemicals from biomass are not produced in competition with food production and do not have a negative impact on the environment or natural habitats. EFPIA White Paper on Circular Economy, June 2020. Org Process Res Dev 2020, 24, 10, 1996–2003. Recycling of medical plastics.

article thumbnail

Exforge antitrust settlement caps Novartis’ year of legal disputes

Pharmaceutical Technology

The alleged actions violated the Hatch-Waxman Act, formally known as the “Drug Price Competition and Patent Term Restoration Act of 1984,” which allows generic manufacturers to market their generic versions of previously approved generic medications. These actions allegedly led to the extension of Novartis’ patents.

article thumbnail

Rare disease partnership champions market access in South America

Pharmaceutical Technology

As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape.

Medical 105